News
Swiss pharma company Idorsia announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has ...
The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback